Xeltis CEO Eliane Schutte has been included in the Healthcare Technology Report’s list of 2021 Top 50 Healthcare Technology CEOs, one of only seven women featuring on the list. The Report’s list recognizes the most accomplished executives in the [...]
Promising early outcomes from two clinical trials of Xeltis pulmonary valve confirm the excellent safety and performance of its bio-restorative RestoreXTM technology. Published in the peer-reviewed journal Frontiers, the data included results from the First-in-Human Xplore-1 trial conducted in [...]
Xeltis bio-restorative pulmonary heart valves and their clinical outcomes will feature at the upcoming Pediatric Device Innovators Forum organized by the U.S. Food and Drug Administration (FDA) in conjunction with five U.S. pediatric device consortia on 11 March. “I [...]
CEO Eliane Schutte will share the latest updates on Xeltis bio-restorative technology platform at the upcoming BioCapital Europe meeting, organized by healthcare investment firm LSP on 11 March. “We have reached some important milestones across our portfolio, confirming the unique [...]
Jochen Reinöhl joins Xeltis as Chief Medical Officer, bringing to the company extensive experience in medical affairs from his previous role at Edwards Lifesciences. Prior to his corporate career, he worked for over ten years at the Department of [...]
Xeltis is among seven European companies selected to join the prestigious research network ArtMoMa. The program aims to reach new heights in the emerging field of artificial molecular machines, including supramolecular technology. ArtMoMa is built on synergies and complementarities between [...]
Deutsche - Xeltis has been selected with three other Swiss companies to illustrate how medtech innovation can pave new ways to improve patients’ lives at the Spirit of Bern conference on 27th February. The Xeltis technology enables patients that [...]
For more on the data, please click here CEO announced continuation of the clinical trial program for the pulmonary valve in EU, Asia and USA Clinical trial results of Xeltis pulmonary valve (PV) show promising functionality of the living valves [...]
Xeltis closed a €10.5 million Series D financing round to support its vascular and valve trial programs this week. The funding was provided by existing institutional and private investors, including all venture capital funds (VCs) already financing the company. [...]